Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

Elevations in C-reactive protein (CRP) are associated with increased cardiovascular disease (CVD) risk, increased HIV disease progression, and death in HIV-infected patients. Use of abacavir has been reported to increase CVD risk. We assessed the effect of virologically suppressive efavirenz (EFV)-based antiretroviral therapy on high sensitivity CRP (hsCRP) levels over a 96-week period with particular attention to the effect of gender and abacavir use. Banked sera from entry and week 96 visits of AIDS Clinical Trials Group A5095 participants were assayed for hsCRP, then analyzed by gender, abacavir randomization, and for correlation with changes in fasting metabolic parameters. Analyses of hsCRP were conducted in two phases and involved a total of 145 men and 51 women. hsCRP did not differ by gender at baseline but higher levels were seen at week 96 in women (median 6 mg/liter; Q1, Q3, 1.8, 13.8) compared to men (median 1.6 mg/liter; Q1, Q3, 0.9, 4.2, p < 0.001), with an estimated shift in hsCRP by gender of 2.5 mg/liter (95% CI 1.0, 5.1). There was no difference in hsCRP levels by abacavir use. Changes in hsCRP did not correlate with changes in insulin resistance or with changes in fasting lipids. Durably virologically suppressive therapy with EFV-based regimens did not decrease hsCRP levels over a 96-week period. hsCRP levels increased significantly only in women. Randomization to abacavir had no effect on changes in hsCRP levels. Changes in hsCRP levels did not correlate with changes in fasting metabolic parameters.

[1]  D. Costagliola,et al.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. , 2010, Archives of internal medicine.

[2]  O. Kirk,et al.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. , 2010, The Journal of infectious diseases.

[3]  J. Morrow,et al.  Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study , 2009, Journal of acquired immune deficiency syndromes.

[4]  J. Meigs,et al.  Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction , 2009, Journal of acquired immune deficiency syndromes.

[5]  D. Lapierre,et al.  Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects , 2009, Journal of acquired immune deficiency syndromes.

[6]  J. Lundgren.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients , 2008, AIDS.

[7]  J. Lekakis,et al.  Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. , 2008, Atherosclerosis.

[8]  M. Laakso,et al.  Gender differences in C‐reactive protein, interleukin‐1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population‐based study , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[9]  C. Lewis,et al.  Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels: The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study , 2008, Journal of acquired immune deficiency syndromes.

[10]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[11]  F. Gonano,et al.  Effects of Third-Generation Oral Contraceptives on High-Sensitivity C-reactive Protein and Homocysteine in Young Women , 2008, Obstetrics and gynecology.

[12]  S. Buchbinder,et al.  Body weight and oral contraceptives are the most important modulators of serum CRP levels , 2008, Scandinavian journal of clinical and laboratory investigation.

[13]  F. Gutiérrez,et al.  The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. , 2007, Atherosclerosis.

[14]  W. Fawzi,et al.  C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting , 2007, AIDS.

[15]  K. Tashima,et al.  Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) , 2007, Journal of acquired immune deficiency syndromes.

[16]  I. Kushner,et al.  What does minor elevation of C-reactive protein signify? , 2006, The American journal of medicine.

[17]  B. Lau,et al.  C-reactive protein is a marker for human immunodeficiency virus disease progression. , 2006, Archives of internal medicine.

[18]  E. Yeh,et al.  Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.

[19]  R. Lees,et al.  Increased Cardiovascular Disease Risk Indices in HIV-Infected Women , 2005, Journal of acquired immune deficiency syndromes.

[20]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[21]  S. Hammer,et al.  C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s , 2004, AIDS.

[22]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[23]  N. Cook,et al.  Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores , 2004, Circulation.

[24]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[25]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[26]  J. Feldman,et al.  C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection , 2003, Journal of acquired immune deficiency syndromes.

[27]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[28]  N. Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[29]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.